ETON
Eton Pharmaceuticals, Inc. (ETON) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
ETON still shows a high-growth profile with revenue per share of 3.82 and strong profitability metrics supporting continued expansion potential.
Return on equity is 40.1% and return on invested capital is 20.4%, indicating the business can compound capital efficiently.
Financial Strength
Liquidity remains acceptable with a current ratio of 1.52 and quick ratio of 1.30.
Leverage is modest with debt-to-equity at 0.62 and net debt to EBITDA at 0.12, suggesting limited balance-sheet stress.
Profitability Quality
Gross margin is 57.9% and net margin is 12.0%, showing solid underlying economics.
Operating margin of 15.4% and interest coverage of 6.1x indicate the company is converting sales into earnings reasonably well.
Cash Generation
Free cash flow yield is only 0.9% and price-to-free-cash-flow is elevated at 114.3x, limiting near-term cash-return appeal.
Operating cash flow remains positive, but free cash flow per share of 0.53 is modest relative to the valuation.
Valuation
Valuation remains stretched with price-to-earnings at 132.2x and price-to-sales at 15.9x.
Enterprise value to EBITDA of 90.8x implies the market is pricing in substantial future growth.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Eton Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

